GENinCode (LON:GENI) Stock Price Up 11.8% – Time to Buy?

Shares of GENinCode Plc (LON:GENI) shot up 11.8% on Tuesday . The company traded as high as GBX 1 and last traded at GBX 0.95. 6,288,954 shares were traded during trading, an increase of 14% from the average daily volume of 5,528,808 shares. The stock had previously closed at GBX 0.85.

GENinCode Trading Up 11.8%

The business has a fifty day simple moving average of GBX 0.90 and a 200-day simple moving average of GBX 1.05. The company has a debt-to-equity ratio of 117.74, a quick ratio of 15.88 and a current ratio of 0.93. The firm has a market cap of £7.15 million, a price-to-earnings ratio of -0.46 and a beta of 0.59.

GENinCode (LON:GENI) last announced its quarterly earnings results on Monday, June 8th. The company reported GBX (2.08) EPS for the quarter. The firm had revenue of GBX 308 million for the quarter. GENinCode had a negative net margin of 185.47% and a negative return on equity of 409.40%. As a group, equities analysts forecast that GENinCode Plc will post -7.1299999 earnings per share for the current fiscal year.

GENinCode Company Profile

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.